A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

JRCT ID: jRCT2041220057

Registered date:19/08/2022

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: ER+ HER2- Locally Advanced or Metastatic Breast Cancer
• Date of first enrollment: 16/08/2022
• Target sample size: 9
• Study type: Interventional

Intervention(s)

Drug: ARV-471
ARV-471 will be administered orally QD with food, in
continuous dosing over 28-day cycles.

Outcome(s)

Primary Outcome

Dose Limited Toxicities (DLTs) [ Time Frame: Time Frame: Up to 29 days ]
Number of participants with dose-limiting toxicities (DLTs)

Secondary Outcome

1. Safety and Tolerability as assessed by adverse event monitoring for participants. [ Time Frame: Up to 24 months ]
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.
2. Safety and Tolerability through monitoring of laboratory assessments for participants. [ Time Frame: Up to 24 months ]
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.
3. Single Dose: AUC from time zero to time tau (AUCtau) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
4. Single Dose: AUC from time zero to time of last measurable concentration (AUClast) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
5. Single Dose: Maximum Observed Concentration (Cmax) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
6. Single Dose: Time to Maximum concentration (Tmax) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
7. Single Dose: Terminal Elimination half-life (t1/2) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
8. Single Dose: Metabolite Ratio Cmax (MRCmax) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
9. Multiple Dose: AUC from time zero to time tau (AUCtau) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
10. Multiple Dose: AUC from time zero to time of last measurable concentration (AUClast) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
11. Multiple Dose: Maximum Observed Concentration (Cmax) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
12. Multiple Dose: Minimum Observed Concentration (Cmin) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
13. Multiple Dose: Trough Observed Concentration (Ctrough) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
14. Multiple Dose: Apparent total clearance (CL/F) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471
15. Multiple Dose: Time to Maximum concentration (Tmax) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
16. Multiple Dose: Apparent volume of distribution (Vz/F) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471
17. Multiple Dose: accumulation ratio based on AUC (observed) (Rac) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
18. Multiple Dose: Terminal Elimination half-life (t1/2) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
19. Multiple Dose: Effective half-life based on accumulation ratio (t1/2eff) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
20. Multiple Dose: Metabolite Ratio Cmax (MRCmax) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
21. Multiple Dose: Metabolite Ratio AUCtau (MRAUCtau) [ Time Frame: Up to 24 months ]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
22. Overall Response Rate (ORR) in participants [ Time Frame: Up to 24 months ]
23. Clinical Benefit Response (CBR) based on the summation of complete Response (CR), Partial Response (PR) and Stable Disease (SD) of 24 weeks duration or longer in participants [ Time Frame: Up to 24 months ]
24. Progression Free Survival (PFS) observed in participants [ Time Frame: Up to 24 months ]
25. Duration of Response (DOR) in participants [ Time Frame: Up to 24 months ]

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Inclusion Criteria:
1. Participants (women and men) at least 20 years of age at the time of signing the informed consent.
2. Histological or cytological diagnosis of ER+/HER2- advanced breast cancer that is metastatic, recurrent, or locally advanced unresectable breast cancer.
3. Participants who are resistant to standard therapy or for which no standard therapy is available or have received.
4. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Infromed Consent
Document (ICD) and in this protocol.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
6. Adequate Bone Marrow or Coagulation Function.
7. Adequate Renal Function, defined as an estimated creatinine clearance >=60 mL/min as calculated using the method standard for the institution.
8. Adequate Liver Function.
9. Participants with brain metastases must meet all the specified conditions.
10. Resolution of acute effects of any prior therapy to either baseline severity or CTCAE version 5.0 Grade <=1.

Exclude criteria

Exclusion Criteria:
1. Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen's disease.
2. Participants sustaining major surgery defined as a complex procedure performed under regional or general anesthesia with a recovery period of at least 4 weeks prior to study enrollment.
3. Known or suspected hypersensitivity or severe allergy to active ingredient/excipients of ARV-471.
4. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
5. Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow. Palliative radiation for the
alleviation of pain due to bone metastasis will be allowed during the study.
6. Concurrent administration of medications, foods or herbal supplements that are strong inhibitors or inducers of cytochrome CYP3A4, substrates
of P-gp, sensitive substrates of CYP2B6, proton pump inhibitors, or medicines known risk of causing Torsade de Pointes. Prior use of strong
CYP3A inhibitors must be stopped 7 days and strong CYP3A inducers must be stopped 14 days before randomization.
7. Prior treatment with ARV-471.
8. Systemic anticancer therapy chemotherapy or endocrine therapy within 14 days prior to study entry (6 weeks for mitomycin C or nitrosoureas). If the last immediate anticancer treatment contained an antibody-based agent(s) (approved or investigational), then an interval of 28 days or 5 half-lives (whichever is shorter) of the agent(s) prior to receiving the study intervention treatment is required.
9. Participants who have initiated therapy with bone-modifying agents (bisphosphonates, denosumab, or similar) within 14 days of enrollment.
10. Previous high-dose chemotherapy requiring stem cell rescue.
11. Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry. A participant may be eligible even if they are
in the follow-up phase of an investigational study as long as they haven't received treatment in the study for 5 half lives of the agents.
12. Serum pregnancy test (for females of childbearing potential) positive at screening and/or a breastfeeding participant.
13. Participants with active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and known Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness.
14. Baseline standard 12 lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or
interpretation of study results.
15. Any of the following in the previous 12 months: myocardial infarction, long QT syndrome, Torsade de Pointes, clinically important atrial or
ventricular arrhythmias, serious conduction system abnormalities, unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF,New York Heart Association class III or IV, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, and/or other clinical significant episode of thrombo-embolic disease. Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, atrial fibrillation of any grade. If a participant has a cardiac rhythm device/pacemaker placed and QTcF >470 ms, the participant may be considered eligible. Participants with cardiac rhythm device/pacemaker must be discussed in detail with the sponsor to judge eligibility.
16. History of symptomatic cardiac valve disease.
17. Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.

Related Information

• Primary Sponsor: Kawai Norisuke
• Secondary ID(s): NCT05463952